{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=3", "query": { "condition": "Normal Subjects", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2506, "total_pages": 251, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T14:26:05.341Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05366179", "title": "Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "CAR.B7-H3T cells infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2022-09-02", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05366179" }, { "nct_id": "NCT05695950", "title": "A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatomyositis" ], "interventions": [ { "name": "GLPG3667", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lakefront Biotherapeutics NV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2023-02-27", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Upland, California • Kendall, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Upland", "state": "California" }, { "city": "Kendall", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05695950" }, { "nct_id": "NCT01498874", "title": "Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "gevokizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XOMA (US) LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 127, "start_date": "2011-12", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-03-04", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 19, "location_summary": "Hot Springs, Arkansas • Riverside, California • San Diego, California + 16 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498874" }, { "nct_id": "NCT00522834", "title": "Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Elesclomol (STA-4783)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synta Pharmaceuticals Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2007-08", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2014-03-04", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 61, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00522834" }, { "nct_id": "NCT01384630", "title": "Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "RA-18C3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2011-09-30", "completion_date": "2012-08-31", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 3, "location_summary": "Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas", "locations": [ { "city": "Owensboro", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01384630" }, { "nct_id": "NCT01583530", "title": "Study of Belimumab Administered Subcutaneously to Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Single Dose Group: Belimumab IV 240 mg", "type": "BIOLOGICAL" }, { "name": "Single Dose Group: Belimumab SC 2 x 120 mg", "type": "BIOLOGICAL" }, { "name": "Single Dose Group: Belimumab SC 1 x 240 mg", "type": "BIOLOGICAL" }, { "name": "Single Dose Group: Belimumab SC 1 x 200 mg", "type": "BIOLOGICAL" }, { "name": "Multiple Dose Group: Belimumab SC 2 x 120 mg weekly", "type": "BIOLOGICAL" }, { "name": "Multiple Dose Group: Belimumab SC 1 x 200 mg weekly", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 118, "start_date": "2011-02", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2013-08-07", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 4, "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01583530" }, { "nct_id": "NCT00833599", "title": "Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphedema", "Lymphatic Disorders", "Lipedema", "Vascular Malformation", "Vascular Anomaly", "Dercum Disease" ], "interventions": [ { "name": "NIRFLI with ICG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Months", "maximum_age": null, "sex": "ALL", "summary": "3 Months and older" }, "enrollment_count": 283, "start_date": "2009-01", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 3, "location_summary": "Houston, Texas • The Woodlands, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833599" }, { "nct_id": "NCT03431974", "title": "Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "LD-Aminopterin oral capsule", "type": "DRUG" }, { "name": "Placebo oral capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syntrix Biosystems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2018-11-01", "completion_date": "2021-01-11", "has_results": true, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Seattle, Washington • Spokane, Washington", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Seattle", "state": "Washington" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03431974" }, { "nct_id": "NCT01888874", "title": "Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "GLPG0634", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lakefront Biotherapeutics NV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 599, "start_date": "2013-07-17", "completion_date": "2015-05-14", "has_results": true, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 28, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hemet", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888874" }, { "nct_id": "NCT01506609", "title": "Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2012-01-23", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-10-22T14:26:05.341Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01506609" } ] }